We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
A ranking of pharma companies developing new medicines for low- and middle-income countries has revealed that just five companies are responsible for almost two-thirds of projects.